← Back to search

Enanta Pharmaceuticals Inc

ENTA · NASDAQ

Pharmaceutical Preparation Manufacturing

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

ESG Scores

Overall ESG
2.9
Environmental
3.1
Social
3.0
Governance
5.9

Gender Diversity

Female Directors0.2857%
CEO GenderMale